Imunon Analysis: $13M Raised
What is Imunon?
Imunon develops innovative medicines that leverage the body's immune system. Their proprietary platforms focus on difficult-to-treat conditions, utilizing immunology and DNA-based technologies. This approach aims to provide transformative therapeutic benefits for patients facing serious health challenges.
Employees
11-50
Industry
Biotech, HealthTech
Product Features & Capabilities
- Proprietary immunology platforms for cancer treatment
- DNA-based vaccines for infectious diseases
- Clinical development of nucleic acid-based therapies
- Research and development in oncology
- Innovative therapeutic solutions for challenging medical conditions.
Use Cases
Developing anti-cancer therapies using nucleic acid technology; Conducting clinical trials for vaccine development; Partnering with research institutions for innovative solutions; Addressing vaccine-preventable diseases through advanced therapies; Enhancing patient outcomes in oncology and infectious diseases.
How much Imunon raised
Not specified (likely a Series or Private Placement) - $10 million
August 16, 2024Lead Investor: Not specified
Private Placement - $3.25 million
May 28, 2025Lead Investor: H.C. Wainwright & Co. (Lead Placement Agent), Brookline Capital Markets (Co-Placement Agent)
Other Considerations
Nasdaq listed under IMNN; Leadership team with over 50 years of combined experience; Engaged in clinical trials for ovarian cancer therapies.
